glp-1 cardiovascular outcomes 2025 news of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice Bridging the gap between GLP1-receptor

In October, in a move the organization hadnt made since the late 1980s, Blue Cross offered buyouts to hundreds of employees

Recent innovations, such as new subcutaneous injection devices and inhalable formulations, cater to patient preferences for convenience and needle-free options

It found people taking tirzepatide for type 2 diabetes lost as much as 12 pounds more than people taking a 1-milligram dose of semaglutide for 40 weeks

Compounded vs brand-name Powerful active ingredient

"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA." The Lancet , 2023